NCI-Sponsored Multidisciplinary Study of MR Imaging of Intravenous Superparamagnetic Crystalline Particle Ferumoxytol in Primary High-grade Brain Tumors and/or Cerebral Metastases From Lung or Breast Cancer
This protocol revision to the preliminary trial will characterize vascular properties of
tumors in the CNS using ferumoxytol for DSC MRI to compare with those obtained using GBCA
for DCE in a single MR imaging session. Furthermore, these imaging properties of various
malignant CNS tumors will be characterized longitudinally with up to 6 imaging session over
approximately 2 years. The information obtained in this study may guide the creation of a
new imaging criteria to evaluate tumor progression and pseudoprogression secondary to RCT in
the context of wide-spread use of antiangiogenic agents. We expect that characterizing the
vascular properties of tumors in the CNS using ferumoxytol for DSC MRI in order to compare
with those obtained using GBCA for DCE MRI, will be achievable as in a single imaging
session.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Investigate the utility of ferumoxytol and GBCA for improved imaging biomarkers of malignant brain tumors in a single imaging session by comparing DSC determined rCBV and DCE determined vascular permeability (Ktrans).
2 years
No
Edward A. Neuwelt, MD
Principal Investigator
OHSU Knight Cancer Institute
United States: Federal Government
OHSU-813
NCT00103038
May 2009
December 2013
Name | Location |
---|---|
OHSU Knight Cancer Institute | Portland, Oregon 97239 |